Workflow
Yatai pharm(002370)
icon
Search documents
亚太药业:亚太药业业绩说明会、路演活动信息
2023-05-15 08:16
浙江亚太药业股份有限公司 投资者关系活动记录表 编号:2023-001 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 √业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他(请文字说明其他活动内容) | | 参与单位名称及人员 | 投资者网上提问 | | 姓名 | | | 时间 | 2023 年 5 月 12 日(周五) 15:00-17:00 | | 地点 | 公司通过 全 景 网 " 投 资 者 关 系 互 动平台 " | | | (https://ir.p5w.net)采用网络远程的方式召开业绩说 | | | 明会 | | 形式 | 采用网络远程方式举行 | | 上市公司接待人员姓 | 董事长宋凌杰 | | | 董事、总经理黄小明 | | | 董事会秘书徐炜 | | 名 | 财务总监徐景阳 | | | 独立董事吕海洲 | | 投资者关系活动主要 | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回 | | | 复: | | | 1、希望大股东和二股东要有格局,转 ...
亚太药业(002370) - 关于参加浙江辖区上市公司2023年投资者网上集体接待日活动暨网上业绩说明会的公告
2023-05-08 10:21
证券代码:002370 证券简称:亚太药业 公告编号:2023-033 债券代码:128062 债券简称:亚药转债 浙江亚太药业股份有限公司 关于参加浙江辖区上市公司 2023 年投资者网上集体接待日 活动暨网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整,没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,浙江亚太药业股份有限公司 (以下简称"公司")将参加由浙江证监局、浙江省上市公司协会与 深圳市全景网络有限公司联合举办的"2023 年浙江辖区上市公司投 资者集体接待日活动"暨 2022 年度网上业绩说明会,现将相关事项 公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路 演"网站(https://rs.p5w.net),或关注微信公众号:全景财经, 或下载全景路演 APP,参与本次互动交流,活动时间为 2023 年 5 月 12 日(周五)15:00-17:00。 届时公司董事长宋凌杰先生,董事、总经理黄小明先生,董事会 秘书徐炜先生,财务总监徐景阳先生,独立董事吕海洲先生(如有特 殊情况,参与人员会有调整)将在线就公司 2022 年度业 ...
亚太药业:关于参加浙江辖区上市公司2023年投资者网上集体接待日活动暨网上业绩说明会的公告
2023-05-08 10:21
本公司及董事会全体成员保证信息披露的内容真实、准确、完 整,没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,浙江亚太药业股份有限公司 (以下简称"公司")将参加由浙江证监局、浙江省上市公司协会与 深圳市全景网络有限公司联合举办的"2023 年浙江辖区上市公司投 资者集体接待日活动"暨 2022 年度网上业绩说明会,现将相关事项 公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路 演"网站(https://rs.p5w.net),或关注微信公众号:全景财经, 或下载全景路演 APP,参与本次互动交流,活动时间为 2023 年 5 月 12 日(周五)15:00-17:00。 届时公司董事长宋凌杰先生,董事、总经理黄小明先生,董事会 秘书徐炜先生,财务总监徐景阳先生,独立董事吕海洲先生(如有特 殊情况,参与人员会有调整)将在线就公司 2022 年度业绩、公司治 理、发展战略、 经营状况等投资者关心的问题,与投资者进行沟通 与交流,欢迎广大投资者踊跃参与! 为提高互动交流的效率,现提前向所有关心公司的投资者公开征 集交流问题,广泛听取投资者的意见和建议。投资者可于 2023 年 ...
亚太药业(002370) - 2023 Q1 - 季度财报
2023-04-28 16:00
Financial Performance - The company's revenue for Q1 2023 was ¥123,584,310.47, representing an increase of 80.88% compared to ¥68,322,640.18 in the same period last year[4] - The net loss attributable to shareholders was ¥2,618,854.09, a 90.93% improvement from a loss of ¥28,871,344.89 in the previous year[4] - The net cash flow from operating activities improved by 73.72%, amounting to -¥2,493,862.07 compared to -¥9,488,898.62 in Q1 2022[10] - The company reported a significant increase in fair value gains of 156.76%, totaling ¥3,391,937.73, compared to a loss of -¥5,975,757.73 in the same period last year[8] - The weighted average return on equity improved to -0.87% from -6.89% year-on-year, reflecting a positive trend in financial performance[4] - The company reported a net loss of CNY 3,000,000 for Q1 2023, compared to a net loss of CNY 22,000,000 in the same period last year, indicating an improvement in financial performance[18] - The total comprehensive income for the first quarter was -2,618,854.09 CNY, compared to -28,871,344.89 CNY in the same period last year[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,491,227,644.74, a decrease of 2.13% from ¥1,523,620,705.13 at the end of the previous year[4] - The total assets as of the end of Q1 2023 were CNY 1,491,227,644.74, down from CNY 1,523,620,705.13 at the beginning of the year, a decrease of approximately 2.1%[16] - The total liabilities decreased to CNY 1,192,626,158.72 from CNY 1,222,400,365.02, reflecting a reduction of about 2.4%[16] Revenue and Expenses - The total operating revenue for Q1 2023 was CNY 123,584,310.47, an increase from CNY 68,322,640.18 in the same period last year, representing an increase of approximately 81.1%[18] - The total operating costs for Q1 2023 were CNY 126,382,479.22, up from CNY 90,768,431.38 in the previous year, indicating a rise of about 39.2%[18] - The gross profit margin for Q1 2023 was approximately -2.3%, compared to a gross profit margin of about 39.0% in the same period last year, reflecting a significant decline[18] - The total operating expenses increased to 69,756,339.18 CNY from 54,745,897.69 CNY, reflecting a rise of about 27.4%[22] - Research and development expenses rose to 4,608,303.89 CNY, compared to 3,772,402.86 CNY in the previous year, marking an increase of approximately 22.0%[20] Cash Flow and Equivalents - The company's cash and cash equivalents at the end of Q1 2023 were CNY 739,004,798.75, down from CNY 757,616,775.10 at the beginning of the year, a decrease of about 2.4%[14] - The cash and cash equivalents at the end of the period were 703,824,887.55 CNY, down from 778,696,857.36 CNY at the end of the previous year[22] - The net cash flow from investing activities improved by 43.31%, amounting to -¥1,136,941.50 compared to -¥2,005,559.40 in the previous year[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 72,891, with the largest shareholder holding 14.38% of the shares[11] - The basic and diluted earnings per share were both -0.0049 CNY, compared to -0.0538 CNY in the same quarter last year[20] Litigation - The company is currently involved in ongoing litigation related to securities false statements, with a total claim amount of CNY 8,556,600 from 238 investors, of which 145 have withdrawn their claims[13] Other Information - The company did not report any significant new product launches or technological advancements during this quarter[23]
亚太药业(002370) - 2022 Q4 - 年度财报
2023-04-24 16:00
Financial Performance - Zhejiang Yatai Pharmaceutical reported a revenue of RMB 1.2 billion for 2022, representing a year-on-year increase of 15%[1]. - The company achieved a net profit of RMB 200 million, up 10% compared to the previous year[1]. - The company's operating revenue for 2022 was ¥373,440,356.84, representing an 18.50% increase compared to ¥315,134,248.97 in 2021[19]. - The net profit attributable to shareholders for 2022 was -¥132,720,460.20, a 41.86% improvement from -¥228,280,314.38 in 2021[19]. - The net cash flow from operating activities for 2022 was ¥12,040,719.56, a significant increase of 413.25% compared to -¥3,843,770.44 in 2021[20]. - The total assets at the end of 2022 were ¥1,523,620,705.13, a decrease of 5.41% from ¥1,610,781,365.72 at the end of 2021[20]. - The net assets attributable to shareholders decreased by 30.43% to ¥301,220,340.11 in 2022 from ¥432,961,573.08 in 2021[20]. - The basic earnings per share for 2022 was -¥0.25, improving from -¥0.43 in 2021[20]. - The company reported a weighted average return on equity of -36.12% for 2022, an improvement from -41.76% in 2021[20]. - The company achieved total operating revenue of ¥373,440,356.84 in 2022, representing an 18.50% increase compared to the previous year[48]. - The net profit attributable to shareholders was ¥-132,720,460.20, reflecting a 41.86% increase year-on-year[48]. Market Expansion and Product Development - User data indicates a growth in customer base by 20%, reaching 1 million active users[1]. - The company plans to launch three new products in 2023, focusing on innovative drug development[1]. - Future guidance estimates a revenue growth of 12% for 2023, targeting RMB 1.34 billion[1]. - Zhejiang Yatai Pharmaceutical is expanding its market presence in Southeast Asia, with a projected investment of RMB 50 million[1]. - The company is focusing on high-end generic drugs and innovative drug development as part of its strategy to maintain competitiveness in the pharmaceutical industry[41]. - The company is actively exploring OEM and CMO/CDMO projects to enhance sales and market presence[45]. - The company plans to continue its innovation-driven strategy, focusing on the development of generic drugs and enhancing its R&D capabilities[48]. - The company is focusing on enhancing its production capacity and efficiency to meet the increasing demands of the pharmaceutical market[81]. Research and Development - The company has multiple ongoing R&D projects aimed at enriching its product line, including non-fluorinated drugs and various injectable formulations[62]. - The company has obtained drug registration certificates for several products, including non-fluorinated tablets and capsules, which are expected to be launched soon[62]. - Research and development expenses decreased by 33.53% to ¥26,805,928.47, accounting for 7.18% of operating revenue, down from 12.80% in the previous year[63]. - The number of R&D personnel decreased by 23.08% to 90, with the proportion of R&D staff in total employees dropping to 16.95% from 20.03%[63]. - The company is actively advancing the consistency evaluation process for key generic drug products to mitigate risks associated with regulatory compliance[95]. Regulatory Environment and Risks - Risk factors include potential regulatory changes and increased competition in the pharmaceutical sector, which the company is actively monitoring[1]. - The overall regulatory environment is becoming more stringent, which may impact operational strategies but also supports the development of innovative products[32]. - The implementation of centralized procurement policies may lead to significant changes in drug bidding and pricing, potentially compressing profit margins[92]. - The company faces risks from regulatory changes in the pharmaceutical industry, which could impact operations if strategies are not adjusted accordingly[92]. - The company is facing risks in drug research and development due to long cycles, high investment, and potential delays or failures, which could impact future growth[94]. Corporate Governance and Compliance - The company is committed to enhancing its governance structure, ensuring compliance with relevant laws and regulations, and protecting shareholder rights[99]. - The board of directors operates with clear responsibilities and has established specialized committees to provide professional advice for decision-making[99]. - The company emphasizes transparency in information disclosure, ensuring all investors have equal access to relevant information[100]. - The company has established a complete organizational structure, including independent procurement, production, and sales systems[103]. - The company has a fully independent financial department, with separate bank accounts and no shared accounts with controlling shareholders[103]. - The company is committed to improving compliance and governance following recent regulatory scrutiny[124]. Legal and Financial Liabilities - The company is currently in the process of legal proceedings regarding the disputes[181]. - The outcome of the litigation could have significant implications for the company's future financial health[181]. - The company has received a civil judgment requiring the payment of compensation within ten days of the ruling[165]. - The company is actively managing its legal disputes and has taken steps to appeal unfavorable judgments[182]. - The company is facing potential financial liabilities due to the ongoing litigation[181]. Environmental and Social Responsibility - The company is committed to environmental protection and will enhance safety management to mitigate risks associated with production waste[93]. - The company has invested in environmental protection measures and has passed ISO14001 certification, demonstrating its commitment to sustainable practices[158]. - The company has implemented effective measures for the treatment of solid waste, ensuring compliance with hazardous waste management regulations[151]. - The company has developed an emergency response plan for environmental incidents, ensuring timely and effective resolution of any issues[153].
亚太药业(002370) - 2014年11月21日投资者关系活动记录表
2022-12-07 09:31
Group 1: Antibiotic Business Overview - In 2013, antibiotics accounted for 59.97% of the company's total sales, indicating its primary revenue source [2] - The implementation of antibiotic restrictions has impacted sales, prompting the company to adopt a strategy focused on stability [2] - The company is gradually shifting towards non-antibiotic products while updating its antibiotic formulations [3] Group 2: Marketing and Sales Strategy - The company is optimizing its marketing system and continuously adjusting its sales channels to strengthen distribution control [3] - A dual sales structure combining agents and self-built teams is being established to enhance promotional efforts [3] Group 3: Pricing and Regulatory Environment - There is a trend towards the deregulation of drug prices, but the actual implementation depends on national policies [3] Group 4: Diagnostic Reagents Business - Revenue from diagnostic reagents was 5.5286 million yuan in 2013 and 3.2230 million yuan in the first half of 2014, indicating a need for market layout [3] - The company plans to enhance diagnostic reagent performance by increasing personnel, expanding the market, and diversifying the product line [3] Group 5: Estradiol Patch Market Potential - Estradiol patches are used to treat symptoms related to estrogen deficiency during menopause, with market recognition gradually increasing [4] - The overall market size is currently small, and patient awareness of alternative therapies needs improvement [4]
亚太药业(002370) - 2016年7月14日投资者关系活动记录表
2022-12-07 00:02
Group 1: Company Strategy and Development - The company aims to acquire 100% of Shanghai New Summit to diversify its business from chemical drugs to new drug research outsourcing services, enhancing competitiveness and optimizing business structure [3] - Future collaboration with New Summit will focus on new drug screening, clinical trials, and resource integration to improve overall profitability [3] - The company plans to leverage its capital platform for mergers and acquisitions in high-value sectors like new drug development and high-end medical devices [3] Group 2: Market Position and Risks - The CRO business model of New Summit is characterized by high efficiency and strong brand advantages, but faces risks such as intense market competition and long contract cycles [4] - The company has seen a 39% year-on-year increase in non-antibiotic revenue, surpassing antibiotic revenue for the first time, while costs increased by 33.56% [6] - The antibiotic business revenue decreased by 10.86% year-on-year, prompting the company to focus on improving existing product quality and developing new antibiotic varieties [6] Group 3: Product Development and Evaluation - The company is actively working on consistency evaluations for its existing oral formulations, with 19 products listed among the first 289 requiring evaluation [5] - Current clinical services primarily focus on pre-market evaluations, with plans to expand into clinical trial networks [4] - The company is developing new products, including linezolid and esomeprazole magnesium enteric-coated capsules, with clinical trials underway for linezolid [7]
亚太药业(002370) - 2016年7月15日投资者关系活动记录表
2022-12-06 23:56
Group 1: Business Overview - The main business of Zhejiang Apac Pharmaceutical Co., Ltd. includes the research, production, and sales of chemical preparations, chemical raw materials, and diagnostic reagents, with chemical preparations being the primary source of revenue [3]. - The company currently has approximately 30-40 products on the market, focusing on optimizing product structure and increasing the proportion of non-antibiotic specialty products [3]. - Future collaboration with Xinshengyuan will enhance drug screening research, consistency evaluation, and clinical trials, aiming to expand overall business scale and improve profitability [3]. Group 2: Strategic Goals - The company plans to leverage its capital platform for mergers and acquisitions in high-value sectors such as new drug development and high-end medical devices, aligning with its strategic goal of industrial transformation and upgrading [3]. - The management is committed to improving operational performance despite challenges in predicting future business performance due to bidding conditions [4]. Group 3: Market Position and Future Plans - Xinshengyuan, as a platform-based CRO, emphasizes efficient GRDP management and aims to build a network of clinical teams and hospitals for consistency evaluation, which is a key focus for future business development [4]. - The company acknowledges its late entry into the market and is considering the development of new fields and products in the future [5]. Group 4: Shareholder and Management Insights - The major shareholder currently has no intention of increasing or decreasing their stake, and there are no plans for equity incentives for management [4].
亚太药业(002370) - 2016年7月20日投资者关系活动记录表
2022-12-06 23:36
Group 1: Company Overview - Zhejiang Apac Pharmaceutical Co., Ltd. is engaged in the pharmaceutical industry, focusing on drug research and development [2] - The company operates as a Contract Research Organization (CRO), providing comprehensive research services from preclinical to clinical studies [3] Group 2: Financial Performance and Projections - According to the equity transfer agreement, the company commits to achieving annual net profits of no less than CNY 106.25 million, CNY 132.81 million, and CNY 166.02 million for the years 2016, 2017, and 2018 respectively [3] - The company has approximately 300 employees, with 50% engaged in research and development services [3] Group 3: Business Development Strategies - The company aims to expand into high-value sectors such as new drug development and medical devices to achieve strategic transformation [4] - The consistency evaluation business is a key focus for future growth, with active efforts to build clinical teams and hospital networks [4] Group 4: Product Development and Market Strategy - The company currently markets around 30-40 products, primarily in the antibiotic and non-antibiotic categories, with a focus on optimizing product structure and increasing the proportion of non-antibiotic products [4] - The company is developing a flexible talent introduction mechanism, combining project-based recruitment and collaboration [5] Group 5: Regulatory and Market Challenges - The two-invoice system may exert significant pressure on drug pricing, leading to new commercial rules [5] - Due to the complexities of the bidding process, it is challenging to predict operational performance for the next two years [5] Group 6: Capital Raising Activities - The company’s non-public stock issuance received approval from the China Securities Regulatory Commission on July 6, 2016, and is currently in the process of related matters [5]
亚太药业(002370) - 2022 Q3 - 季度财报
2022-10-27 16:00
浙江亚太药业股份有限公司 2022 年第三季度报告 证券代码:002370 证券简称:亚太药业 公告编号:2022-089 浙江亚太药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入(元) | 72,632,930.79 | 10.74% | 234,144,248.88 | 7.29% | | 归属 ...